Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
BRUSSELS, BELGIUM & SOUTH SAN FRANCISCO, CALIFORNIA – March 19, 2013 . – UCB and Five Prime Therapeutics announced today that they have entered into a strategic collaboration for the discovery of innovative biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases
Toggle Summary Mark McDade to join FivePrime Board of Directors
Mark McDade to join FivePrime Board of Directors San Francisco -  Five Prime Therapeutics, Inc. today announced that it has appointed Mark McDade, CEO of PDL BioPharma, Inc, to the FivePrime Board of Directors.   “We are delighted to have Mark join our Board”, said Lewis T.

Upcoming and Recent Events > MORE

Date Event Details
Summary Toggle Thursday, June 14, 2018 8:00 AM PDT
Summary Toggle Thursday, June 07, 2018 11:00 AM EDT


Francis Sarena
Chief Strategy Officer and Secretary

Supporting Materials

Summary Toggle Tuesday, May 08, 2018 4:30 PM EDT